The Final ImResFun Scientific Conference of the EC-funded Marie-Curie Initial Training Network ImResFun is now announced.

Publication: Candidalysin is a fungal peptide toxin critical for mucosal infection

ITN Practical Course "C2a", Barcelona, Spain (May 10-15, 2015)

ITN Meeting, La Colle sur Loup, France (May 16, 2015)

HPF2015, La Colle sur Loup, France (May 16-22, 2015)

ITN Practical Course "S3" & "C3", Madrid, Spain (July 6-10, 2015)

ITN Mid-Term Review Meeting, Vienna, Austria (November 3, 2015)

ITN Practical Course "S5" & "C5", Tübingen, Germany (May 9-11, 2016)

ITN Lecture Course "S4" & "C4", Szeged, Hungary (July 2-8, 2016)

ITN Practical Course "S6" & "C6", Göttingen, Germany (October 26-28, 2016)

ITN Symposium "S7" & Final Consortium Meeting, Innsbruck, Austria (January 28-30, 2017)


Name & Address

Thomas Lion Portrait

Thomas Lion, MD, PhDProfessor and Medical Director
Labdia Labordiagnostik GmbH
St. Anna Kinderkrebsforschung
Zimmermannplatz 8, 1090 Vienna, Austria
Phone: +43(1)40077-4890 (Secretary: -4800) FAX: +43(1)40077-64890
e-mail: &

ESR-LabDia Project: (Start November/December 2013)

Identification of prognostic biomarkers in invasive fungal diseases

To develop a novel approach to rapid detection of fungi adn bacteria in clinical samples and to develop a molecular understanding the complex interactions between specific bacterial and fungal pathogens, including the mutual promoting/inhibitory effects on growth and pathogenicity.

Main Research Interests

Research, development (R&D) and diagnostics in the field of microbiology and chronic myeloid leukemia (CML) are the major areas of activity in our division. The exploitation of diagnostic assays emanating from our R&D work and the performance of specific developmental tasks were transferred to LabDia Labordiagnostik, a non-profit institution established in 2006 as a subsidiary of the St.Anna Childern´s Cancer Research Organization. A major part of our work is focused on infectious problems in oncological patients undergoing allogeneic stem cell transplantation (allo-SCT) or chemotherapy. In addition to bacteria, viral and fungal pathogens are particularly frequent causes of life-threatening infections in severely immunocompromised children. Early and reliable diagnosis is an essential prerequisite for successful therapy. We have therefore developed and, in part, patented quantitative molecular detection assays for many pathogenic viruses and clinically relevant fungal species. We were able to demonstrate that the clinical implementation of various methods developed in our division permits early assessment of impending infectious complications (Landlinger et al. Leukemia 2010; Lion et al. Leukemia 2010). The new diagnostic approaches will therefore contribute to improved treatment strategies against life-threatening infections in severely immunocompromised patients.

An additional focus of our activities is the diagnostic monitoring of patients after allo-SCT. A European project coordinated by our center has led to the establishment of a standardized methodology for quantitative analysis of patient- and donor-derived cells (chimerism) (Lion et al. Leukemia 2012). The patented technique will soon be commercially available as a diagnostic kit. Moreover, we have recently established a diagnostic approach facilitating very early prediction of graft rejection which will permit timely therapeutic interventions (Breuer et al. Leukemia 2012).

Our recent development and clinical implementation of a molecular technique for the surveillance of mutant, therapy-resistant subclones in patients with CML provided important information on clonal development of the disease, timely detection of resistance, and clone-specific responses to treatment (Preuner et al. EJC 2012). The new insights will facilitate ensuing research which will improve our understanding of the dynamics of this type of leukemia. We will be able to pursue this task within a recently granted long-term project (Special Research Area Program funded by Austrian FWF).

Selected Recent Publications

Preuner S & Lion T (2013). Species-Specific Identification of a Wide Range of Clinically Relevant Fungal Pathogens by the Luminex(®) xMAP Technology. Methods Mol Biol. 2013;968:119-39. doi: 10.1007/978-1-62703-257-5_9.

Landlinger C, Preuner S, Bašková L, van Grotel M, Hartwig NG, Dworzak M, Mann G, Attarbaschi A, Peters C, Matthes-Martin S, Lawitschka A, van den Heuvel-Eibrink MM & Lion T (2010). Diagnosis of invasive fungal infections by a real-time panfungal PCR assay in immuncompromised pediatric patient Leukemia 24(12):2032-8.

Landlinger C, Preuner S, Willinger B, Haberpursch B, Racil Z, Mayer J, Lion T (2009). Species-specific identification of a wide range of clinically relevant fungal pathogens by use of Luminex xMAP technology. J Clin Microbiol. 47(4):1063-73.